Issuu on Google+

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email!

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017 Published on January 2012

Report Summary Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017 Summary 'Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017', a new report by Global Markets Direct, provides key market data on the Greece In Vitro Diagnostics market. The report provides value (USD million), for each segment and sub-segment within seven market categories ' Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on key recent developments. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Direct's team of industry experts. Scope - Market size and company share data for In Vitro Diagnostics market categories ' Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. - Annualized market revenues (USD million) for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017. - 2010 company shares and distribution shares data for each of the seven market categories. - Global corporate-level profiles of key companies operating within the Greece In Vitro Diagnostics market. - Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., bioMerieux S.A. and others. Reasons to buy - Develop business strategies by identifying the key market categories and segments poised for strong growth. - Develop market-entry and market expansion strategies. - Design competition strategies by identifying who-stands-where in the Greece In Vitro Diagnostics competitive landscape. - Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future. - What are the key distribution channels and what's the most preferred mode of product distribution ' Identify, understand and capitalize.

Table of Content 1 Table of Contents

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017 (From Issuu)

Page 1/9


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! 1 Table of Contents 2 1.1 List of Tables 6 1.2 List of Figures 8 2 Introduction 10 2.1 What is This Report About' 10 3 In Vitro Diagnostics In Greece 11 3.1 In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual, 2003-2017 11 3.2 In Vitro Diagnostics, Greece, Company share (2009-2010) 17 4 Clinical Chemistry In Greece 19 4.1 Clinical Chemistry Overall Revenue (2003-2017) 19 4.1.1 Clinical Chemisty Analyzers Revenue (2003-2017) 23 4.1.2 Urine Analysis Revenue (2003-2017) 27 4.2 Clinical Chemistry Distribution Share (2009-2010) 31 4.3 Clinical Chemistry, Greece, Company share (2009-2010) 32 5 Genetic Testing In Greece 34 5.1 Genetic Testing Overall Revenue (2003-2017) 34 5.2 Genetic Testing Distribution Share (2009-2010) 38 5.3 Genetic Testing, Greece, Company share (2009-2010) 39 6 Haematology In Greece 41 6.1 Haematology Overall Revenue (2003-2017) 41 6.1.1 Haematology Reagents Revenue (2003-2017) 45 6.1.2 Immunohaematology Revenue (2003-2017) 49 6.1.3 Haemostasis Revenue (2003-2017) 53 6.1.4 Haematology Rapid Tests Revenue (2003-2017) 57 6.1.5 Haematology Cell Counters Revenue (2003-2017) 61 6.2 Haematology Distribution Share (2009-2010) 65 6.3 Haematology, Greece, Company share (2009-2010) 66 7 Histology And Cytology In Greece 68 7.1 Histology And Cytology Overall Revenue (2003-2017) 68 7.2 Histology And Cytology Distribution Share (2009-2010) 72 7.3 Histology And Cytology, Greece, Company share (2009-2010) 73 8 Immuno Chemistry In Greece 75 8.1 Immuno Chemistry Overall Revenue (2003-2017) 75 8.1.1 Disease Specific Immunochemistry Revenue (2003-2017) 79 8.1.2 Drugs of Abuse / Toxicology Revenue (2003-2017) 83 8.1.3 Endocrinology Tests Revenue (2003-2017) 87 8.1.4 Therapeutic Drug Monitoring Revenue (2003-2017) 91 8.1.5 Immunochemistry Analyzers Revenue (2003-2017) 95 8.2 Immuno Chemistry Distribution Share (2009-2010) 99 8.3 Immuno Chemistry, Greece, Company share (2009-2010) 100 9 Infectious Immunology In Greece 102 9.1 Infectious Immunology Overall Revenue (2003-2017) 102 9.2 Infectious Immunology Distribution Share (2009-2010) 106 9.3 Infectious Immunology, Greece, Company share (2009-2010) 107 10 Microbiology Culture In Greece 109 10.1 Microbiology Culture Overall Revenue (2003-2017) 109 10.1.1 Microbiology Analyzers Revenue (2003-2017) 113 10.2 Microbiology Culture Distribution Share (2009-2010) 117

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017 (From Issuu)

Page 2/9


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! 10.3 Microbiology Culture, Greece, Company share (2009-2010) 118 11 Overview of Key Companies in Greece In Vitro Diagnostics Market 120 11.1 F. Hoffmann-La Roche Ltd. 120 11.1.1 Company Overview 120 11.2 Siemens Healthcare 120 11.2.1 Company Overview 120 11.3 Abbott Laboratories 120 11.3.1 Company Overview 120 11.4 Beckman Coulter, Inc. 121 11.4.1 Company Overview 121 11.5 Ortho-Clinical Diagnostics Inc. 121 11.5.1 Company Overview 121 11.6 bioMerieux S.A. 121 11.6.1 Company Overview 121 11.7 Sysmex Corporation 122 11.7.1 Company Overview 122 11.8 Bio-Rad Laboratories, Inc. 122 11.8.1 Company Overview 122 11.9 Becton, Dickinson and Company 122 11.9.1 Company Overview 122 11.10 Phadia AB 123 11.10.1 Company Overview 123 11.11 DiaSorin S.p.A 123 11.11.1 Company Overview 123 11.12 DIAGNOSTICA STAGO, Inc. 123 11.12.1 Company Overview 123 11.13 PerkinElmer, Inc. 124 11.13.1 Company Overview 124 11.14 Thermo Fisher Scientific Inc. 124 11.14.1 Company Overview 124 11.15 Qiagen N.V. 124 11.15.1 Company Overview 124 11.16 Grifols, S.A. 125 11.16.1 Company Overview 125 11.17 HORIBA, Ltd. 125 11.17.1 Company Overview 125 11.18 Gen-Probe Incorporated 125 11.18.1 Company Overview 125 11.19 Immucor, Inc. 126 11.19.1 Company Overview 126 11.20 Life Technologies Corporation 126 11.20.1 Company Overview 126 11.21 Danaher Corporation 126 11.21.1 Company Overview 126 11.22 Hologic, Inc. 127 11.22.1 Company Overview 127 11.23 Cellestis Limited 127 11.23.1 Company Overview 127

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017 (From Issuu)

Page 3/9


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! 12 Financial Deals Landscape 128 12.1 Partnerships 128 12.1.1 Biofortuna Enters Into Distribution Agreement With Abbott 128 12.1.2 Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics 129 13 APPENDIX 130 13.1 Global Markets Direct Research Methodology 130 13.2 Definitions of Markets Covered in the Report 131 13.2.1 In Vitro Diagnostics 131 13.3 Secondary Research 142 13.4 Primary Research 142 13.5 Models 143 13.6 Forecasts 143 13.7 Expert Panel Validation 143 13.8 Currency Conversion 144 13.9 Contact Us 144 13.10 Disclaimer 144 List of Tables Table 1:

In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual, 2003-2017 12

Table 2:

In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual, Historic, 2003-2010 14

Table 3:

In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 16

Table 4:

In Vitro Diagnostics, Greece, Company share by Revenue ($m), USD Actual, 2009-2010 18

Table 5:

Clinical Chemistry, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 20

Table 6:

Clinical Chemistry, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 22

Table 7:

Clinical Chemisty Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 24

Table 8:

Clinical Chemisty Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 26

Table 9:

Urine Analysis, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 28

Table 10:

Urine Analysis, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 30

Table 11:

Clinical Chemistry, Greece, Distribution Share by Revenue ($m), USD Actual, 2009-2010 31

Table 12:

Clinical Chemistry, Greece, Company share by Revenue ($m), USD Actual 2009-2010 33

Table 13:

Genetic Testing, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 35

Table 14:

Genetic Testing, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 37

Table 15:

Genetic Testing, Greece, Distribution Share by Revenue ($m), USD Actual, 2009-2010 38

Table 16:

Genetic Testing, Greece, Company share by Revenue ($m), USD Actual 2009-2010 40

Table 17:

Haematology, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 42

Table 18:

Haematology, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 44

Table 19:

Haematology Reagents, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 46

Table 20:

Haematology Reagents, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 48

Table 21:

Immunohaematology, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 50

Table 22:

Immunohaematology, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 52

Table 23:

Haemostasis, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 54

Table 24:

Haemostasis, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 56

Table 25:

Haematology Rapid Tests, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 58

Table 26:

Haematology Rapid Tests, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 60

Table 27:

Haematology Cell Counters, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 62

Table 28:

Haematology Cell Counters, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 64

Table 29:

Haematology, Greece, Distribution Share by Revenue ($m), USD Actual, 2009-2010 65

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017 (From Issuu)

Page 4/9


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Table 30:

Haematology, Greece, Company share by Revenue ($m), USD Actual 2009-2010 67

Table 31:

Histology And Cytology, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 69

Table 32:

Histology And Cytology, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 71

Table 33:

Histology And Cytology, Greece, Distribution Share by Revenue ($m), USD Actual, 2009-2010 72

Table 34:

Histology And Cytology, Greece, Company share by Revenue ($m), USD Actual 2009-2010 74

Table 35:

Immuno Chemistry, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 76

Table 36:

Immuno Chemistry, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 78

Table 37:

Disease Specific Immunochemistry, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 80

Table 38:

Disease Specific Immunochemistry, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 82

Table 39:

Drugs of Abuse / Toxicology, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 84

Table 40:

Drugs of Abuse / Toxicology, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 86

Table 41:

Endocrinology Tests, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 88

Table 42:

Endocrinology Tests, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 90

Table 43:

Therapeutic Drug Monitoring, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 92

Table 44:

Therapeutic Drug Monitoring, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 94

Table 45:

Immunochemistry Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 96

Table 46:

Immunochemistry Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 98

Table 47:

Immuno Chemistry, Greece, Distribution Share by Revenue ($m), USD Actual, 2009-2010 99

Table 48:

Immuno Chemistry, Greece, Company share by Revenue ($m), USD Actual 2009-2010 101

Table 49:

Infectious Immunology, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 103

Table 50:

Infectious Immunology, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 105

Table 51:

Infectious Immunology, Greece, Distribution Share by Revenue ($m), USD Actual, 2009-2010 106

Table 52:

Infectious Immunology, Greece, Company share by Revenue ($m), USD Actual 2009-2010 108

Table 53:

Microbiology Culture, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 110

Table 54:

Microbiology Culture, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 112

Table 55:

Microbiology Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 114

Table 56:

Microbiology Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 116

Table 57:

Microbiology Culture, Greece, Distribution Share by Revenue ($m), USD Actual, 2009-2010 117

Table 58:

Microbiology Culture, Greece, Company share by Revenue ($m), USD Actual 2009-2010 119

Table 59:

Biofortuna Enters Into Distribution Agreement With Abbott 128

Table 60:

Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics 129

Table 61: USD to Local Currency, Greece, Average Actual Rate 2003-2010 144 List of Figures Figure 1:

In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual, 2003-2017 11

Figure 2:

In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual, Historic, 2003-2010 13

Figure 3:

In Vitro Diagnostics, Greece, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 15

Figure 4:

In Vitro Diagnostics, Greece, Company share (%), 2010 17

Figure 5:

Clinical Chemistry, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 19

Figure 6:

Clinical Chemistry, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 21

Figure 7:

Clinical Chemisty Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 23

Figure 8:

Clinical Chemisty Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 25

Figure 9:

Urine Analysis, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 27

Figure 10:

Urine Analysis, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 29

Figure 11:

Clinical Chemistry, Greece, Company share (%), 2010 32

Figure 12:

Genetic Testing, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 34

Figure 13:

Genetic Testing, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 36

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017 (From Issuu)

Page 5/9


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Figure 14:

Genetic Testing, Greece, Company share (%), 2010 39

Figure 15:

Haematology, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 41

Figure 16:

Haematology, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 43

Figure 17:

Haematology Reagents, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 45

Figure 18:

Haematology Reagents, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 47

Figure 19:

Immunohaematology, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 49

Figure 20:

Immunohaematology, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 51

Figure 21:

Haemostasis, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 53

Figure 22:

Haemostasis, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 55

Figure 23:

Haematology Rapid Tests, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 57

Figure 24:

Haematology Rapid Tests, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 59

Figure 25:

Haematology Cell Counters, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 61

Figure 26:

Haematology Cell Counters, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 63

Figure 27:

Haematology, Greece, Company share (%), 2010 66

Figure 28:

Histology And Cytology, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 68

Figure 29:

Histology And Cytology, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 70

Figure 30:

Histology And Cytology, Greece, Company share (%), 2010 73

Figure 31:

Immuno Chemistry, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 75

Figure 32:

Immuno Chemistry, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 77

Figure 33:

Disease Specific Immunochemistry, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 79

Figure 34:

Disease Specific Immunochemistry, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 81

Figure 35:

Drugs of Abuse / Toxicology, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 83

Figure 36:

Drugs of Abuse / Toxicology, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 85

Figure 37:

Endocrinology Tests, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 87

Figure 38:

Endocrinology Tests, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 89

Figure 39:

Therapeutic Drug Monitoring, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 91

Figure 40:

Therapeutic Drug Monitoring, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 93

Figure 41:

Immunochemistry Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 95

Figure 42:

Immunochemistry Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 97

Figure 43:

Immuno Chemistry, Greece, Company share (%), 2010 100

Figure 44:

Infectious Immunology, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 102

Figure 45:

Infectious Immunology, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 104

Figure 46:

Infectious Immunology, Greece, Company share (%), 2010 107

Figure 47:

Microbiology Culture, Greece, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 109

Figure 48:

Microbiology Culture, Greece, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 111

Figure 49:

Microbiology Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 113

Figure 50:

Microbiology Analyzers, Greece, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 115

Figure 51:

Microbiology Culture, Greece, Company share (%), 2010 118

Figure 52:

Global Markets Direct Methodology 130

Companies Mentioned F. Hoffmann-La Roche Ltd. Siemens Healthcare Abbott Laboratories Beckman Coulter, Inc. Ortho-Clinical Diagnostics Inc. bioMerieux S.A. Sysmex Corporation

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017 (From Issuu)

Page 6/9


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! Bio-Rad Laboratories, Inc. Becton, Dickinson and Company Phadia AB DiaSorin S.p.A DIAGNOSTICA STAGO, Inc. PerkinElmer, Inc. Thermo Fisher Scientific Inc. Qiagen N.V. Grifols, S.A. HORIBA, Ltd. Gen-Probe Incorporated Immucor, Inc. Life Technologies Corporation Danaher Corporation Hologic, Inc. Cellestis Limited

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017 (From Issuu)

Page 7/9


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: ƒ ƒ

Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93

If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information Please verify that the product information is correct and select the format(s) you require. Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017

Product Formats Please select the product formats and the quantity you require. 1 User License--USD 2 500.00

Quantity: _____

Site License--USD 5 000.00

Quantity: _____

Corporate License--USD 7 500.00

Quantity: _____

Contact Information Please enter all the information below in BLOCK CAPITALS

Title:

Mr

Mrs

Dr

Miss

Ms

Prof

First Name:

_____________________________ Last Name: __________________________________

Email Address:

__________________________________________________________________________

Job Title:

__________________________________________________________________________

Organization:

__________________________________________________________________________

Address:

__________________________________________________________________________

City:

__________________________________________________________________________

Postal / Zip Code:

__________________________________________________________________________

Country:

__________________________________________________________________________

Phone Number:

__________________________________________________________________________

Fax Number:

__________________________________________________________________________

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017 (From Issuu)

Page 8/9


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card

Card Number: ______________________________________________

Expiry Date

__________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer

Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check

UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

 

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms

Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56

ƒ ƒ

Asia, Oceania and America : + 1 (805) 617 17 93

Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017 (From Issuu)

Page 9/9


Greece In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017